Astria Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATXS research report →
Companywww.astriatx.com
Astria Therapeutics, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema.
- CEO
- Jill C. Milne
- IPO
- 2015
- Employees
- 78
- HQ
- Boston, MA, US
Price Chart
Valuation
- Market Cap
- $718.13M
- P/E
- -5.88
- P/S
- 1017.18
- P/B
- 3.13
- EV/EBITDA
- -4.67
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -19335.69%
- Net Margin
- -17567.99%
- ROE
- -45.01%
- ROIC
- -54.66%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-94,260,000 · -29.32%
- EPS
- $-1.68 · 30.58%
- Op Income
- $-111,558,000
- FCF YoY
- -19.08%
Performance & Tape
- 52W High
- $13.29
- 52W Low
- $3.56
- 50D MA
- $12.74
- 200D MA
- $8.32
- Beta
- 0.02
- Avg Volume
- 1.07M
Get TickerSpark's AI analysis on ATXS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 23, 26 | Violin Jonathan | sell | 14,100 |
| Jan 23, 26 | Violin Jonathan | sell | 8,333 |
| Jan 23, 26 | Violin Jonathan | sell | 14,100 |
| Jan 23, 26 | Violin Jonathan | sell | 263,321 |
| Jan 23, 26 | Violin Jonathan | sell | 14,166 |
| Jan 23, 26 | Violin Jonathan | sell | 26,550 |
| Jan 23, 26 | Morabito Christopher | sell | 80,000 |
| Jan 23, 26 | Morabito Christopher | sell | 262,500 |
| Jan 23, 26 | Milne Jill C. | sell | 761,000 |
| Jan 23, 26 | Milne Jill C. | sell | 4,377 |
Our ATXS Coverage
We haven't published any research on ATXS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ATXS Report →